Biotech Stock News (SRPT) (BMRN) (ACAD)

Sarepta Therapeutics (NASDAQ:SRPT) On Monday April 25, 2016 Sarepta Therapeutics had an FDA advisory panel shoot down its drug Eteplirsen, used to treat patients with Duchenne Muscular Dystrophy — DMD. The panel voted against Eteplirsen on all questions. Even the last question which asked if Eteplirsen should be approved for DMD patients was also voted … Read more

Biotech Stock News (ACAD) (RXII) (REGN) (AZN) (ZSPH)

Acadia Pharmaceuticals (NASDAQ:ACAD) On November 3, 2015 Acadia had announced that the FDA had given its Parkinson’s Drug, NUPLAZID, FDA priority review. To understand what this means, we must first understand what the FDA priority review actually means? A company is only given FDA priority review if the drug it has developed treats an unmet … Read more

Biotech Stock News (RXII) (REGN) (SURG) (VRX) (ACAD)

Rxi Pharmaceuticals (NASDAQ:RXII) On August 31, 2015 Rxi announced that the 30-day review period for its IND of RXI-109 for scarring of macular degeneration has passed its review period and the IND is now active. The whole point of the 30-day review period is for the FDA to look at pre-clinical data and conclude whether … Read more

Biotech Stock News (ACAD) (CUR) (AMRN)

Acadia Pharmaceuticals (ACAD) Shares of Acadia Pharmaceuticals tanked around 30% in after hours trade on 3/11/15 after it had announced two different sets of news. The first set of news was that the CEO of Acadia Uli Hacksell would not only be stepping down as the CEO of the company but stepping down from the … Read more